Start a Conversation.

Five service areas: Drug Response Screening, Combination Therapy Profiling, Ex Vivo Clinical Trial Support, Functional Precision Oncology Research, and Customised Solutions. Every project is designed around your biological question, study objectives, and translational goals rather than a fixed catalogue package.

A patient-derived organoid is a three-dimensional tumor model grown from patient tissue that retains much of the architecture and biology of the original tumor. Compared with flat cell-line cultures, it gives a more human-relevant read on how a compound behaves, before costly in vivo work.

No. All 3DxCell services are for research use only. Results support drug development, translational oncology, and clinical research; they are not intended for clinical diagnosis or to direct treatment decisions for an individual patient.

No. 3DxCell provides research services to pharmaceutical companies, biotech firms, academic institutions, and clinical research partners. Patients interested in organoid-based research should speak with their treating oncologist.

Yes. We are based in Lund, Sweden and work with pharma, biotech, and academic groups across Europe and beyond. Samples are shipped to our facility under validated conditions, and all reporting is delivered digitally.

With a free, informal scientific consultation of roughly 30–60 minutes, where we assess feasibility and ask the right scientific questions. A written proposal follows within 3–5 business days; after agreement, kickoff and sample logistics take 1–2 weeks.

Yes, and we encourage it. We are happy to sign a mutual NDA before any substantive scientific discussion or data sharing. Contact us and we will respond within 1 business day.

No. Every project is scoped individually: the number of models, compounds, assay complexity, and deliverables all shape it. You receive a written proposal with transparent pricing before any commitment, and the first conversation is free.

No. The request form captures the shape of your study (service area, number of compounds and models, and which deliverables you need), so we can scope it quickly. Anything shown there is indicative; only the written proposal is binding.

Most projects run about 6–8 weeks in total, from kickoff to final report. Larger cohort work under Ex Vivo Clinical Trial Support takes longer. The timeline is fixed in the proposal before any work begins.

We share a sample acquisition protocol at kickoff. Fresh material is normally shipped in specialised transport media under defined temperature conditions, and we coordinate directly with your clinical team or biobank.

Results are generated for you and delivered to you. Ownership of data and of any resulting intellectual property is set out in the agreement signed before kickoff, and everything shared in both directions is treated as confidential.

Yes. We work with academic groups on mechanistic studies, biomarker research, resistance modeling, and translational research projects. Academic collaboration frameworks are available. Tell us about the study and we will scope it accordingly.

Our validated model library covers colorectal, lung (NSCLC/SCLC), breast (ER+, HER2+, TNBC), pancreatic (PDAC), and bladder cancers. Other indications are possible where model establishment is part of the project scope.

Yes. Organoid Establishment from eligible samples can be built into the scope, with cohort-level model tracking where relevant. Feasibility depends on the indication and on sample access, so it is the first thing we discuss.

A Comprehensive Final Study Report covering study design, assay conditions, controls, analysis methodology, statistical evaluation, and an integrated interpretation of the results, with raw and processed data as accompanying files. Depending on the service, Drug Response Analysis, Morphology Assessment, Histopathology & Marker Profiling, and Genomic Profiling are included or optional.

Yes. Combination Therapy Profiling characterises functional responses to combination therapies and includes Combination Response Analysis: combination response matrices, graphical summaries, and synergy scoring using established models (Loewe, Bliss, HSA) where it suits the study design.

Yes. Ex Vivo Clinical Trial Support is built for cohort-level work: response distribution across the cohort, differential response patterns, candidate responder subgroups, and biomarker-informed stratification to support clinical development strategies.

Model characterisation is a standard part of the workflow: histopathological assessment, immunophenotypic characterization, identity and quality verification, and quality-controlled model selection, all before drug testing starts. Molecular profiling can be added where the study calls for it.

Our workflows are standardized and every study is documented through structured research reporting, which is a solid basis for a regulatory package. Bring your regulatory context into the scoping conversation. The documentation scope is easiest to set before the study design is fixed.